Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “New York”

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic CancerActive Not Recruiting
NCT04340141Phase 3Updated Sep 4, 2026
Sponsor: Alliance for Clinical Trials in Oncology
Pancreatic Adenosquamous Carcinoma · Resectable Pancreatic Adenocarcinoma · Stage I Pancreatic Cancer AJCC v8 · Stage II Pancreatic Cancer AJCC v8
United States, Canada
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruiting
NCT07218341Phase 4Updated Sep 4, 2026
Sponsor: Eli Lilly and Company
Chronic Lymphocytic Leukemia · Lymphoma, Small Lymphocytic
United States, Australia, Austria, Belgium, Canada +12 more
Quality of End-of-Life Care for Children With CancerRecruiting
NCT07412002N/AUpdated Sep 4, 2026
Sponsor: Children's Oncology Group
Childhood Hematopoietic and Lymphatic System Neoplasm · Childhood Malignant Solid Neoplasm
United States
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruiting
NCT06096844Phase 3Updated Sep 4, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma · Stage IIIB Lung Cancer AJCC v8 · Stage IIIC Lung Cancer AJCC v8 · Stage IV Lung Cancer AJCC v8
United States
A Platform Trial for Gram Negative Bloodstream InfectionsRecruiting
NCT06537609NAUpdated Sep 4, 2026
Sponsor: Sunnybrook Health Sciences Centre
Gram-negative Bacteremia
Australia, Canada, Colombia, Israel, New Zealand
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 VaccineNot Yet Recruiting
NCT07703475Phase 1Updated Sep 4, 2026
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
COVID -19
United States
A Study of LY4337713 in Participants With FAP-Positive Solid TumorsRecruiting
NCT07213791Phase 1Updated Sep 4, 2026
Sponsor: Eli Lilly and Company
Ovarian Neoplasms · Breast Neoplasms · Pancreatic Intraductal Neoplasms · Colorectal Neoplasms
United States, China, Germany, Japan, Netherlands
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruiting
NCT07287917Phase 1, Phase 2Updated Sep 4, 2026
Sponsor: Aminex Therapeutics, Inc.
Melanoma (Skin Cancer) · HER2-low Hormone Receptor Positive Breast Cancer
United States
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruiting
NCT06772623Phase 1, Phase 2Updated Sep 4, 2026
Sponsor: AbbVie
Non Small Cell Lung Carcinoma
United States, Australia, Belgium, China, France +10 more
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerRecruiting
NCT06952660Phase 4Updated Sep 4, 2026
Sponsor: Pfizer
Cervical Cancer
United States, Puerto Rico
Symptom Trajectory Approaches to ResearchNot Yet Recruiting
NCT07804875N/AUpdated Sep 4, 2026
Sponsor: University of Wisconsin, Madison
Advanced Cancer · Metastatic Disease · Cancer Treatment · Progressive Disease
United States
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaActive Not Recruiting
NCT04609046Phase 1Updated Sep 4, 2026
Sponsor: National Cancer Institute (NCI)
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
United States
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruiting
NCT06937086Phase 3Updated Sep 4, 2026
Sponsor: Eli Lilly and Company
Ulcerative Colitis · Obesity or Overweight
United States, Austria, Belgium, Brazil, Bulgaria +18 more
Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant RecipientsActive Not Recruiting
NCT07805343N/AUpdated Sep 4, 2026
Sponsor: Paris Translational Research Center for Organ Transplantation
Rejection Acute Renal · Rejection Chronic Renal · Transplantation · Kidney Rejection Transplant
United States, Belgium, Brazil, France, Germany +3 more
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerRecruiting
NCT06510374Phase 3Updated Sep 4, 2026
Sponsor: Ferring Pharmaceuticals
Intermediate Risk Non-Muscle Invasive Bladder Cancer
United States, Canada, Czechia, Denmark, France +4 more
TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasRecruiting
NCT07082803Phase 1Updated Sep 4, 2026
Sponsor: Treeline Biosciences, Inc.
Lymphoma · Lymphoma, Non Hodgkin
United States, Australia, Canada
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityActive Not Recruiting
NCT07311850Phase 3Updated Sep 4, 2026
Sponsor: Pfizer
Obesity and Overweight
United States, Bulgaria, Canada, Czechia, Germany +5 more
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruiting
NCT05112601Phase 2Updated Sep 4, 2026
Sponsor: National Cancer Institute (NCI)
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma
United States
A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruiting
NCT06400472Phase 1Updated Sep 4, 2026
Sponsor: Eli Lilly and Company
Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical Neoplasms · Carcinoma, Non-Small-Cell Lung
United States, Australia, France, Italy, Japan +2 more
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruiting
NCT07198074Phase 3Updated Sep 4, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Endometrial Carcinoma · Recurrent Endometrial Carcinoma
United States
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruiting
NCT07287098Phase 2Updated Sep 4, 2026
Sponsor: Eli Lilly and Company
Breast Neoplasms
United States, Belgium, France, Germany, Ireland +2 more
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Active Not Recruiting
NCT05739383Phase 3Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
United States, Argentina, Australia, Austria, Belgium +37 more
Olfactory Training in Mild Cognitive ImpairmentRecruiting
NCT06825403NAUpdated Sep 4, 2026
Sponsor: Jeffrey Motter
Mild Cognitive Impairment
United States
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyTerminated
NCT02927249Phase 3Updated Sep 4, 2026
Sponsor: Alliance for Clinical Trials in Oncology
Node Positive HER2 Negative Breast Cancer
United States, Canada, Guam, Puerto Rico
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruiting
NCT06937099Phase 3Updated Sep 4, 2026
Sponsor: Eli Lilly and Company
Crohn's Disease · Obesity or Overweight
United States, Austria, Belgium, Brazil, Bulgaria +17 more

Previous page Next page